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Abstract
Background & Aims—Hepatopulmonary syndrome (HPS) affects 10%–30% of patients with
cirrhosis and portal hypertension, but the impact on functional status, quality of life, and survival is
poorly defined. We assessed the impact of HPS in patients evaluated for liver transplantation.
Methods—We performed a prospective multicenter cohort study of patients being evaluated for
liver transplantation in 7 academic centers in the United States. Patients with HPS (defined as an
increased alveolar-arterial oxygen gradient with intrapulmonary vasodilation) were compared with
those without HPS in terms of demographics and clinical variables. New York Heart Association
functional class, quality of life, and survival were assessed.
Results—Seventy-two patients with HPS and 146 patients without HPS were compared. There
were no differences in age, sex, or etiology or severity of liver disease between the groups; however,
patients with HPS were less likely to have a history of smoking (P = .03). Patients with HPS had
worse New York Heart Association functional class (P = .005) and had significantly worse quality
of life in certain domains compared with patients without HPS. In addition, patients with HPS also
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had a significantly increased risk of death compared with patients without HPS despite adjustment
for age, sex, race/ethnicity, Model for End-Stage Liver Disease score, and liver transplantation
(adjusted hazard ratio = 2.41; 95% confidence interval, 1.31–4.41; P = .005).
Conclusions—HPS was associated with a significant increase in risk of death as well as worse
functional status and quality of life in patients evaluated for liver transplantation.
The hepatopulmonary syndrome (HPS) occurs when intrapulmonary vascular dilation leads to
abnormal systemic oxygenation in the setting of liver disease or portal hypertension.1 This
syndrome has been found in 10%–32% of patients with cirrhosis being evaluated for liver
transplantation and may also be seen in noncirrhotic portal hypertension and acute hepatitis.
2–5 Currently, the only established treatment for HPS is liver transplantation.
The mechanism for HPS is currently unknown. Despite this, 2 small single-center studies have
suggested that the presence of HPS may be associated with increased mortality in cirrhotic
patients being evaluated for liver transplantation.6,7 Similarly, survival after liver
transplantation may be lower in patients with HPS relative to those without HPS.5 However,
the association between HPS and the risk of death remains controversial. It is also unclear
whether it is the presence of the syndrome itself or the severity of gas exchange abnormalities
in those with HPS that affects long-term outcome. In addition, whether HPS influences
functional status and quality of life has never been studied.
Therefore, we sought to prospectively evaluate clinical characteristics, functional status, and
survival of patients with HPS compared to those without HPS in a cohort of patients with
advanced liver disease and portal hypertension being evaluated for liver transplantation.
Patients and Methods
Study Design and Study Sample
The Pulmonary Vascular Complications of Liver Disease study enrolled a cohort of 536
patients evaluated for liver transplantation at 7 centers in the United States between 2003 and
2006. The only inclusion criterion was the presence of portal hypertension with or without
intrinsic liver disease. We excluded patients with active infection, with recent (<2 weeks)
gastrointestinal bleeding, or who had undergone prior liver or lung transplantation. The study
was approved by the institutional review board of each center, and patients provided informed
consent.
The study sample included new patients evaluated with contrast echocardiography, spirometry,
and arterial blood gas sampling (tests routinely performed for all patients evaluated for liver
transplantation). We excluded patients with a significant obstructive ventilatory defect, defined
as forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <0.70 with
FEV1 percent predicted <80%, or a significant restrictive ventilatory defect, defined as FVC
percent predicted and (if performed) total lung capacity percent predicted <70%. We also
excluded patients with intracardiac shunting (defined in the following text).
Data Collection and Variables
Patients underwent a physical examination and laboratory assessment. The Model for End-
Stage Liver Disease (MELD) score was calculated.8 The etiology of underlying liver disease,
past medical history, current medications, social history, and New York Heart Association
(NYHA) functional class were recorded. Chest radiography was interpreted locally at each
center. Pulmonary function test results are expressed using sex- and race-specific prediction
equations, where appropriate.9–11 Arterial blood gas sampling was performed while the subject
breathed room air in the seated position.
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Contrast transthoracic echocardiography was interpreted at each center. Agitated saline was
injected via a peripheral vein during imaging. Appearance of micro-bubbles in the left heart
≥3 cardiac cycles after saline injection was considered “late,” consistent with intrapulmonary
shunting. Appearance of microbubbles in the left heart <3 cardiac cycles after venous injection
was considered “early,” consistent with intracardiac shunting. We administered the Liver
Disease Quality of Life 1.0 questionnaire (LDQOL).12 This questionnaire includes the Medical
Outcomes Study Short Form-36 (SF-36) (version 2.0).13
Survival and liver transplantation status and dates were obtained from the medical record, the
subjects’ physicians, the subjects themselves, and the Social Security Death Index as of
December 31, 2006. Patients who were alive were censored at this date.
Criteria for HPS
HPS was defined by (1) contrast echocardiography with late appearance of microbubbles after
venous injection of agitated saline and (2) an alveolar-arterial oxygen gradient ≥15 mm Hg (or
≥20 mm Hg if age older than 64 years), as previously recommended.1 Patients who did not
meet both criteria were considered to be in the non-HPS group. Patients with either “early” or
indeterminate timing of the appearance of microbubbles in the left heart after agitated saline
injection were excluded. Sensitivity analyses were performed after inclusion of patients with
missing data in the non-HPS group and in which HPS was defined by an alveolar-arterial
gradient greater than the upper limit of normal from the Crapo14 and Harris15 regression
equations.
Statistical Analyses
Continuous data were summarized using mean ± SD or median (interquartile range), as
appropriate. Categorical variables were summarized with n (%). We compared patients with
and without HPS using unpaired Student t tests, Wilcoxon rank sum tests, χ2 tests, and Fisher
exact tests, as appropriate. We used bivariate and multivariate linear regression to analyze the
association between HPS status and the LDQOL and SF-36 scales after adjustment for age,
sex, and MELD score.
Survival was assessed using the Kaplan–Meier estimator and Cox proportional hazards models,
and the results are expressed with a hazard ratios (HRs) in bivariate and multivariate analyses.
To determine whether certain characteristics might explain differences in survival between the
2 groups, we included in the models factors believed to be potential confounders and a term
for liver transplantation as a time-varying covariate. We forced age, sex, race, and liver
transplantation into the model and retained other variables that resulted in a change of the HPS
term coefficient by >20%. The proportional hazards assumption was assessed with log-log
plots.
Results
A total of 536 patients were enrolled in the Pulmonary Vascular Complications of Liver Disease
cohort (Figure 1). A total of 473 of these patients (88%) were new evaluations. Of these, 335
(71%) had pulmonary function testing and arterial blood gases, of which 281 (84%) had
interpretable contrast transthoracic echocardiography. We excluded 15 patients (5%) with
intracardiac shunting, leaving 266 patients. Thirty (11%) of these patients had an obstructive
ventilatory defect on spirometry, and 18 (7%) demonstrated a restrictive ventilatory defect,
leaving 218 (82%, or 41% of the total new patient cohort) in the final study sample. We
compared the final study sample with those new patients who were excluded (n = 255). There
were no apparent differences in terms of age, sex, race, ethnicity, body mass index, etiology
of liver disease, MELD score, or smoking history between the groups (data not shown). In
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addition, the median time from the initial diagnosis of liver disease to entry into the study
cohort was 3 years in both groups.
There were 72 patients with HPS and 146 without HPS in the study sample (Table 1). Patients
with HPS had similar age, sex, and etiologies and severity of liver disease compared with those
without HPS. Patients with HPS were more likely to be non-Hispanic white than non-HPS
patients (P = .03). Most patients in both groups had liver disease attributable to alcohol use
and/or hepatitis C infection, and the mean MELD score was 13 in both groups (P = .76). The
median time from diagnosis of liver disease to evaluation for transplantation (and entry into
the study) was 3 years (range, 1–11 years) for patients with HPS compared with 4 years (range,
1–9 years) for non-HPS patients (P = .60). There were no differences between the groups in
reported complications of portal hypertension, prior transjugular intrahepatic portosystemic
shunt placement, or medical comorbidities. Patients with HPS were less likely than non-HPS
patients to be current or past smokers and tended to have a higher prevalence of chronic alcohol
use. We found no differences in the use of diuretics, beta-blockers, prophylaxis for
encephalopathy or spontaneous bacterial peritonitis or nitrates between the groups (data not
shown).
While common in both groups, dyspnea and orthopnea were significantly more frequent in
those with HPS compared with those without (Table 2). Cyanosis was rare but also significantly
more frequent in patients with HPS. There was also significantly more clubbing and asterixis
noted in those with HPS than in those without. There were no differences in laboratory results
between the groups.
Table 3 shows the results from cardiopulmonary testing. Chest radiography showed more
interstitial markings in patients with HPS than in those without. FVC percent predicted and
FEV1 percent predicted were slightly lower in HPS versus non-HPS patients, and arterial blood
gas results showed characteristic differences. Transthoracic echocardiography with contrast
showed that patients with HPS had more frequent right atrial and ventricular dilatation and
right ventricular hypertrophy than patients without HPS. Valvular and left-sided cardiac
morphology were similar between the groups.
Patients with HPS had worse NYHA functional class compared with patients without HPS
(Wilcoxon rank sum test, P = .005) (Table 4). A total of 134 patients (62%) returned the
LDQOL questionnaire. Patients who returned the questionnaire were similar to those who did
not in terms of age (53 ± 10 vs 51 ± 9 years), sex (37% vs 40% female), MELD score (13 ± 5
vs 14 ± 5), and prevalence of HPS (31% vs 36%). Table 4 shows the adjusted least square
means (standard errors) for the SF-36 scales; unadjusted results were similar. Patients with
HPS had significantly lower scores (indicating worse quality of life) than non-HPS patients on
the General Health, Role Emotional, Mental Health, and Mental Component Score scales.
Notably, patients with HPS had lower scores on virtually every other SF-36 scale; however,
these and the liver disease–specific scale scores from the LDQOL (data not shown) were not
significantly different from those of the non-HPS patients.
A total of 125 patients (57%) from the study sample were listed for liver transplantation, 69
(32%) underwent transplantation, and 47 (21%) died. There were 361 person-years of follow-
up, and the median follow-up time was 1.7 years. There were no patients lost to follow-up. The
1- and 2-year survival rates were 88% (95% confidence interval [CI], 83%–92%) and 78%
(95% CI, 71%–84%), respectively.
There were no differences between the patients with HPS and the non-HPS patients in terms
of the probability of listing (51% vs 60%, respectively; P = .21) or liver transplantation (29%
vs 33%, respectively; P = .58). Despite these similarities, patients with HPS had a doubling in
the risk of death compared with patients without HPS (HR = 2.03; 95% CI, 1.15–3.60; P = .
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015) (Figure 2 and Table 5). This result was unchanged after adjustment for age, sex, and race/
ethnicity (non-Hispanic white vs other). Further adjustment for MELD score increased the HR
for HPS versus non-HPS (HR = 2.41; 95% CI, 1.31–4.42; P = .005), whereas adjustment for
the performance of liver transplantation did not significantly change this result.
We performed additional analyses after adjusting for other variables, including demographics,
anthropomorphics, liver disease and complications, medical comorbidities, spirometry,
echocardiographic measures, and laboratory measures. None of these variables were
significant confounders. We examined the risk of death associated with the partial pressure of
oxygen while breathing room air and the alveolar-arterial oxygen gradient after adjustment for
HPS status; there were no associations between the partial pressure of oxygen or alveolar-
arterial oxygen gradient in patients with HPS and the risk of death (data not shown).
HPS status met the assumption of proportional hazards in all analyses. There were no
particularly influential subjects in the cohort. We conducted sensitivity analyses to explore the
potential effects on our results due to excluding patients (n = 255) from the study sample. Under
the conservative assumption that excluded patients did not have HPS, the prevalence of HPS
would have been 15% (95% CI, 12%–19%). Patients with HPS still had significantly lower
quality of life than non-HPS patients (including patients with missing data) in terms of the
Mental Component Score, General Health, and Mental Health scales and worse NYHA
functional class (all P < .05). However, the Role Emotional scale scores were no longer
significantly different (P = .09). In addition, patients with HPS continued to have a significantly
increased risk of death compared with the non-HPS patients (including those with missing
data) (HR = 1.72; 95% CI, 1.07–2.76; P = .021). Analysis of data available from the excluded
patients showed that 27 were found to have both an alveolar-arterial oxygen gradient >15 mm
Hg and intrapulmonary shunting, fulfilling 2 major criteria for HPS. Sensitivity analyses with
definitions of HPS using the age-corrected upper limits of normal for alveolar-arterial oxygen
gradient from the Crapo and Harris equations showed similar results (data not shown).
Discussion
We have shown that HPS is a common complication in patients with liver disease who are
referred for evaluation for liver transplantation. Non-Hispanic white patients were more likely
to experience this complication than patients of other races and ethnicities, as were never-
smokers. Notably, type or severity of liver disease and history of complications related to portal
hypertension were not associated with the occurrence of HPS. Patients with HPS had a more
than doubling in the risk of death compared with patients without HPS, which was not
accounted for by differences between the groups in demographics, medical comorbidities, type
or severity of liver disease, cardiopulmonary function, or the use of liver transplantation. In
addition, patients with HPS had significantly worse functional status and poorer quality of life
on a number of scales from the SF-36.
We found that 33% of our patients had HPS based on established diagnostic criteria, in line
with prior studies using similar criteria.1,2,16 We also confirmed prior observations that
intrapulmonary shunting by echocardiography is present in approximately 50% of those
without HPS.2,6 Together these findings support that alterations in the pulmonary
microvasculature are common in cirrhosis. As our findings and prior work have shown that
severity of liver disease and its complications do not affect the risk of HPS,2,7,17 other factors
must account for the susceptibility to HPS. We did show racial and ethnic differences in the
occurrence of HPS, suggesting the possible influence of genetic or environmental factors.
Smoking was actually less common in patients with HPS. Radiographic pulmonary interstitial
changes and echocardiographic changes were more frequently seen in patients with HPS than
in controls, as has been shown in previous studies.18–21
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The most important finding in this study is that HPS was associated with a significantly
increased risk of death. This result persisted even after accounting for age, sex, MELD score,
liver transplantation, and other potential confounders. Prior studies have had important
limitations and have shown conflicting results regarding the association of HPS with mortality.
Two studies have suggested that the presence of HPS increased mortality in patients being
evaluated for liver transplantation,6,7 while a more recent analysis of the United Network of
Organ Sharing database did not.22 The first study showing an increased risk was a small single-
center study of an ethnically homogeneous population with a minority of patients with viral
hepatitis, not representative of the liver transplant population in the United States. The second
was a retrospective single-center study that did not adjust for potential confounders. Finally,
the study of the United Network of Organ Sharing database lacked an operational definition
of HPS. In contrast, ours was a large, multicenter, carefully phenotyped prospective cohort
with an ethnic makeup similar to that of the United Network of Organ Sharing liver transplant
wait list,23 which clearly showed a statistically and clinically significant increase in mortality
irrespective of liver transplantation with complete follow-up on all patients.
The mechanism of the association between HPS and adverse outcomes remains unexplained.
While it has been presumed that hypoxemia is a likely contributor to mortality, we have found
that it is the syndrome itself, rather than the severity of hypoxemia, that impacted on survival.
This novel result suggests that factors such as vasoactive or inflammatory substances may
mediate the effect of HPS on survival in cirrhosis. The only therapy considered effective for
HPS is liver transplantation.1 That the increased risk of death associated with HPS persisted
after adjustment for liver transplantation showed that this association was not attributable to
differential use of liver transplantation. Of course, the efficacy of liver transplantation in
treating HPS cannot be determined in an unbiased way in an observational study such as this.
The significant impact of HPS on survival underscores the need to develop effective medical
therapies and define the utility of liver transplantation for this disease.
HPS also had a negative impact on NYHA functional class. Interestingly, despite the physician
assessment of more dyspnea with less activity in the patients with HPS, these patients did not
believe that the physical components of quality of life, such as self-care, energy level, and
disability, were as affected by HPS as the mental components, including nervousness and
depression, difficulties with work, and self-evaluation of general health. The association of
HPS with both functional status and emotional aspects of quality of life magnifies the impact
of this syndrome on patients with already-reduced quality of life associated with chronic liver
disease. It is not known how the presence of HPS influences perceptions of mental and
emotional well-being, but this finding makes establishment of effective therapy for HPS a high
priority.
There are several limitations to this study. First, we only included patients being considered
for liver transplantation, so we do not know whether our findings are generalizable to all
patients with HPS. Second, there were missing data that excluded some patients and could
result in selection bias. However, the study sample appeared similar to the excluded patients
with respect to multiple measured variables. In addition, sensitivity analyses showed that
effects on survival and quality of life remained after a conservative approach which included
all patients in the analysis. Nevertheless, the precise magnitude of the adverse effects of HPS
on quality of life and survival is not fully defined. Third, it is possible that unmeasured or
imprecisely measured variables could have accounted for the association between HPS and
outcome. However, we collected extensive demographic and clinical data that were included
in multivariate analyses that did not change our conclusions. Finally, our cohort was relatively
small, albeit the largest (and only) prospective multicenter study of patients with HPS.
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In summary, HPS is common in patients being evaluated for liver transplantation and is
associated with significant adverse effects on functional status, quality of life, and survival.
Therefore, HPS is an important and potentially modifiable risk factor for morbidity and
mortality in cirrhosis. Understanding the mechanisms of the adverse effects of HPS and
developing effective medical therapies merit high priority to improve the outcomes of patients
with advanced liver disease.
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Selection of study sample.
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Kaplan–Meier survival estimates of patients with HPS and patients without HPS (No HPS) (n
= 218).
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Table 1
Demographics, Liver Disease Characteristics, and Past Medical History
Variable n HPS (n = 72) No HPS (n = 146) P value
Age (y), mean ± SD 218 52 ± 9 53 ± 10 .86
Female sex, n (%) 218 30 (42) 53 (36) .44
Race/ethnicity, n (%) 218 .03
 Non-Hispanic white 65 (90) 110 (75)
 Hispanic white 3 (4) 18 (12)
 Non-Hispanic black 1 (1) 12 (8)
 Other 3 (4) 6 (4)
Etiology of liver disease, n (%)
 Alcohol 218 28 (39) 60 (41) .76
 Hepatitis C infection 218 33 (46) 67 (46) .99
 Autoimmune hepatitis 218 4 (6) 5 (3) .48
 Nonalcoholic fatty liver disease 218 8 (11) 16 (11) .97
 Hepatitis B infection 218 1 (1) 9 (6) .17
 Primary sclerosing cholangitis 218 2 (3) 11 (8) .23
 Primary biliary cirrhosis 218 4 (6) 7 (5) .81
 Cryptogenic cirrhosis 218 7 (10) 12 (8) .71
MELD score, mean ± SD 218 13 ± 4 13 ± 5 .76
Past medical history, n (%)
 Ascites 218 40 (56) 78 (53) .77
 Variceal bleeding 218 18 (25) 33 (23) .69
 Encephalopathy 217 33 (46) 66 (46) .97
 Spontaneous bacterial peritonitis 218 6 (8) 6 (4) .22
 Hepatocellular carcinoma 218 5 (7) 14 (10) .52
 Hepatic hydrothorax 218 4 (6) 4 (3) .30
 Transjugular intrahepatic portosystemic shunt 218 4 (6) 13 (9) .39
 Chronic obstructive pulmonary disease 217 5 (7) 4 (3) .15
 Venous thromboembolism 217 5 (7) 8 (6) .68
 Diabetes mellitus 217 26 (36) 44 (30) .39
 Hypertension 217 24 (33) 42 (29) .51
 Hypercholesterolemia 217 3 (4) 7 (5) 1.0
 Coronary artery disease 217 1 (1) 4 (3) 1.0
 Hypothyroidism 217 6 (8) 8 (6) .43
 Depression 217 19 (26) 32 (22) .48
 Smoking 218 35 (49) 93 (64) .03
 Chronic alcohol use 215 43 (61) 104 (72) .08
 Intravenous drug use 213 10 (14) 30 (21) .22
 Blood transfusion 191 22 (36) 46 (35) .93
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Table 2
Symptoms, Physical Findings, and Laboratory Evaluation
Variable n HPS No HPS P value
Symptoms, n (%)
 Dyspnea 218 34 (48) 42 (29) .007
 Orthopnea 208 17 (25) 18 (13) .03
 Chest pain 212 6 (9) 13 (9) .89
 Palpitations 211 13 (18) 18 (13) .29
 Syncope 212 8 (11) 7 (5) .09
 Weight loss 215 12 (17) 32 (22) .36
Signs, n (%)
 Cyanosis 215 7 (10) 2 (1) .007
 Jaundice 216 27 (38) 52 (36) .76
 Ascites 217 35 (49) 69 (48) .89
 Lower extremity edema 217 44 (61) 72 (50) .11
Physical examination
 Body mass index (kg/m2), mean ± SD 218 30 ± 6 29 ± 6 .06
 Pulse (beats/min), mean ± SD 218 81 ± 14 75 ± 13 .002
 Systolic blood pressure (mm Hg), mean ± SD 218 123 ± 17 119 ± 19 .13
 Diastolic blood pressure (mm Hg), mean ± SD 218 70 ± 10 70 ± 12 .87
 Room air oxygen saturation (%), mean ± SD 135 96 ± 3 97 ± 2 .005
 Ascites, n (%) 215 29 (40) 58 (41) .97
 Spider angiomata, n (%) 209 26 (37) 56 (39) .78
 Lower extremity edema, n (%) 215 45 (63) 73 (51) .08
 Clubbing, n (%) 214 12 (17) 10 (7) .03
 Asterixis, n (%) 215 9 (13) 5 (4) .02
Laboratory results, median (interquartile range)
 Blood urea nitrogen (mg/dL) 214 12 (10–17) 13 (10–18) .15
 Creatinine (mg/dL) 218 0.9 (0.8–1.1) 0.9 (0.8–1.2) .75
 Hemoglobin (g/dL) 218 12.8 (11.6–14.2) 12.8 (11–13.8) .17
 Platelet count (109/L) 215 94 (62–137) 90 (67–144) .80
 International normalized ratio 218 1.3 (1.2–1.5) 1.3 (1.1–1.5) .66
 Alanine aminotransferase (U/L) 218 39 (26–65) 45 (31–68) .15
 Aspartate aminotransferase (U/L) 218 59 (46–95) 68 (43–96) .67
 Total bilirubin (mg/dL) 218 2.2 (1.2–3.2) 2 (1.3–3.4) .48
 Alkaline phosphatase (U/L) 217 133 (105–202) 132 (92–200) .63
 Total protein (g/dL) 211 7.0 (6.3–7.5) 7.1 (6.5–7.6) .17
 Albumin (g/dL) 212 3.0 (2.6–3.4) 3.1 (2.7–3.6) .16
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Table 3
Cardiopulmonary Testing and Abdominal Imaging
Variable n HPS No HPS P value
Chest radiography, n (%)
 Cardiomegaly 207 9 (13) 12 (9) .30
 Interstitial lung disease 207 5 (7) 1 (1) .02
 Hyperinflation 207 1 (2) 2 (1) 1.0
 Pleural effusion 207 8 (12) 15 (11) .83
Pulmonary function testing, mean ± SD
 FVC (% predicted) 218 86 ± 14 91 ± 15 .045
 FEV1 (% predicted) 218 85 ± 14 91 ± 15 .02
 FEV1/FVC 218 0.77 ± 0.05 0.78 ± 0.06 .41
 Total lung capacity (% predicted) 136 89 ± 17 94 ± 15 .08
 DLCOcorr, (% predicted) 211 54 ± 16 63 ± 15 .0001
Arterial blood gas
 pH, mean ± SD 218 7.45 ± 0.03 7.43 ± 0.04 .006
 pCO2 (mm Hg), mean ± SD 218 33 ± 5 35 ± 5 .04
 pO2 (mm Hg), mean ± SD 218 74 ± 14 90 ± 13 <.0001
 Alveolar-arterial oxygen gradient (mm Hg), median (interquartile
range)
218 27 (20–40) 10 (4–15) <.001
Echocardiography
 Right atrial dilation, n (%) 205 17 (26) 18 (13) .02
 Right ventricular dilation, n (%) 211 28 (41) 38 (27) .03
 Right ventricular hypertrophy, n (%) 211 22 (32) 24 (17) .01
 Right ventricular dysfunction, n (%) 212 5 (7) 3 (2) .12
 Right ventricular systolic pressure (mm Hg), mean ± SD 141 39 ± 16 36 ± 10 .30
 Left atrial size (cm), mean ± SD 195 4.2 ± 0.7 4.0 ± 0.7 .09
 Left ventricular hypertrophy, n (%) 214 26 (38) 48 (33) .37
 Pericardial effusion, n (%) 209 5 (7) 18 (13) .24
 Intrapulmonary shunt, n (%) 218 72 (100) 67 (46) <.001
Abdominal imaging, n (%)
 Splenomegaly 207 51 (80) 113 (79) .91
 Ascites 214 26 (38) 64 (42) .62
DLCOcorr, diffusing capacity of the lung for carbon monoxide corrected for hemoglobin (% predicted).
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Table 4
Functional Status and SF-36 Results
Variable N HPS No HPS P value
NYHA, n (%) 217 .005
 I 12 (17) 48 (33)
 II 35 (49) 62 (43)
 III 19 (26) 33 (23)
 IV 6 (8) 2 (1)
SF-36a n = 42 n = 92
 Physical Component Score 30 (2) 32 (1) .32
 Mental Component Score 37 (2) 43 (2) .02
 General Health 23 (4) 34 (3) .006
 Physical Functioning 34 (5) 40 (4) .20
 Role Physical 27 (6) 36 (5) .08
 Role Emotional 50 (6) 64 (5) .03
 Bodily Pain 44 (5) 48 (4) .51
 Mental Health 53 (4) 63 (3) .01
 Vitality 30 (4) 33 (4) .45
 Social Functioning 43 (6) 50 (5) .28
 Health Transition 3.8 (0.2) 3.5 (0.2) .24
a
Least square mean (SE) adjusted for age (53 years), female sex, and MELD score (13).
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Table 5
Cox Proportional Hazards Models for the Risk of Death (N = 218)
HR of HPS vs no HPS 95% CI P value
Unadjusted 2.03 1.15–3.60 .015
Adjusted for age, sex, and race 1.95 1.09–3.50 .025
Adjusted for age, sex, race, and MELD score 2.41 1.31–4.42 .005
Adjusted for age, sex, race, MELD score, and liver
transplantation
2.41 1.31–4.41 .005
Gastroenterology. Author manuscript; available in PMC 2010 February 19.
